FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC, signaling a regulatory update to the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

SUPPL AP for JEVTANA (CABAZITAXEL)